secwatch.observer — SEC 8-K summary
======================================

Issuer:     Talis Biomedical Corp (—)
CIK:        0001584751
Form:       8-K
Filed at:   2023-07-05T23:59:59+00:00
Accession:  0000950170-23-031488
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talis Biomedical effects 1-for-15 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse split effective July 5, 2023; shares reduce from ~26.9M to ~1.8M.
- Stock begins trading on post-split basis on Nasdaq on July 6 under symbol TLIS.
- No fractional shares; any fractional interest rounded up to one whole share.
- CUSIP number changed to 87424L207; par value unchanged at $0.0001.
- Split intended to raise per-share price to satisfy Nasdaq minimum bid requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1584751/000095017023031488/0000950170-23-031488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1584751/000095017023031488/tlis-20230705.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-031488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer